These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

323 related articles for article (PubMed ID: 30924496)

  • 1. Efficacy of axitinib in patients with metastatic renal cell carcinoma refractory to nivolumab therapy.
    Yoshida K; Takagi T; Kondo T; Kobayashi H; Iizuka J; Fukuda H; Ishihara H; Okumi M; Ishida H; Tanabe K
    Jpn J Clin Oncol; 2019 Jun; 49(6):576-580. PubMed ID: 30924496
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy of Axitinib After Nivolumab Failure in Metastatic Renal Cell Carcinoma.
    Ishihara H; Takagi T; Kondo T; Fukuda H; Tachibana H; Yoshida K; Iizuka J; Okumi M; Ishida H; Tanabe K
    In Vivo; 2020; 34(3):1541-1546. PubMed ID: 32354960
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical outcomes of second-line treatment following prior targeted therapy in patients with metastatic renal cell carcinoma: a comparison of axitinib and nivolumab.
    Suzuki K; Terakawa T; Furukawa J; Harada K; Hinata N; Nakano Y; Fujisawa M
    Int J Clin Oncol; 2020 Sep; 25(9):1678-1686. PubMed ID: 32488547
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Individualised axitinib regimen for patients with metastatic renal cell carcinoma after treatment with checkpoint inhibitors: a multicentre, single-arm, phase 2 study.
    Ornstein MC; Pal SK; Wood LS; Tomer JM; Hobbs BP; Jia XS; Allman KD; Martin A; Olencki T; Davis NB; Gilligan TD; Mortazavi A; Rathmell WK; Garcia JA; Rini BI
    Lancet Oncol; 2019 Oct; 20(10):1386-1394. PubMed ID: 31427205
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical Effectiveness of Targeted Therapies Following Nivolumab Therapy in Patients with Metastatic Renal Cell Carcinoma: A Real-World Study.
    Işık D; Kınıkoğlu O; Akdağ G; Altıntaş YE; Türkoğlu E; Yildirim S; Sürmeli H; Başoğlu T; Odabaş H; Turan N
    Medicina (Kaunas); 2024 Jul; 60(7):. PubMed ID: 39064516
    [No Abstract]   [Full Text] [Related]  

  • 6. Efficacy and Safety of Axitinib Therapy After Nivolumab for Patients With Metastatic Renal Cell Cancer.
    Yasuoka S; Yuasa T; Fujiwara R; Komai Y; Numao N; Yamamoto S; Kondo Y; Yonese J
    Anticancer Res; 2020 Nov; 40(11):6493-6497. PubMed ID: 33109588
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy analyses of axitinib and nivolumab in metastatic renal cell carcinoma after failure of targeted therapy: which is better?
    Halit Aktepe O; Sinem Ardic F; Yuce D; Can Guven D; Guner G; Cagri Yildirim H; Kilickap S; Turker A; Kertmen N; Akin S; Aksoy S; Dizdar O; Yalcin S; Erman M
    J BUON; 2021; 26(5):2067-2073. PubMed ID: 34761618
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Outcomes from treatment of metastatic renal-cell carcinoma following failure of first-line anti-VEGF/VEGFR therapy: real-life evidence on the change of the treatment paradigm.
    Bamias A; Zakopoulou R; Tzannis K; Sakellakis M; Koutsoukos K; Kyriazoglou A; Panagiotou A; Armylagos S; Rokas K; Gotzias D; Boulouta A; Bozionelou V; Stravodimos K; Varkarakis I; Mavroudis D; Dimopoulos MA
    Anticancer Drugs; 2023 Mar; 34(3):413-421. PubMed ID: 36730619
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Low-dose axitinib rechallenge with positive outcomes in a patient with metastatic renal cell carcinoma refractory to interferon α, sunitinib, axitinib, and nivolumab therapies: a case report.
    Murata M; Ikeda Y; Hasegawa G; Nakagawa Y; Nishiyama T
    J Med Case Rep; 2019 Apr; 13(1):98. PubMed ID: 31006385
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Outcomes of axitinib versus sunitinib as first-line therapy to patients with metastatic renal cell carcinoma in the immune-oncology era.
    Numakura K; Muto Y; Naito S; Hatakeyama S; Kato R; Koguchi T; Kojima T; Kawasaki Y; Kandori S; Kawamura S; Arai Y; Ito A; Nishiyama H; Kojima Y; Obara W; Ohyama C; Tsuchiya N; Habuchi T
    Cancer Med; 2021 Sep; 10(17):5839-5846. PubMed ID: 34313025
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Outcomes of patients with metastatic clear-cell renal cell carcinoma treated with second-line VEGFR-TKI after first-line immune checkpoint inhibitors.
    Shah AY; Kotecha RR; Lemke EA; Chandramohan A; Chaim JL; Msaouel P; Xiao L; Gao J; Campbell MT; Zurita AJ; Wang J; Corn PG; Jonasch E; Motzer RJ; Sharma P; Voss MH; Tannir NM
    Eur J Cancer; 2019 Jun; 114():67-75. PubMed ID: 31075726
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A Multicenter Phase II Trial of Axitinib in Patients With Recurrent or Metastatic Non-clear-cell Renal Cell Carcinoma Who Had Failed Prior Treatment With Temsirolimus.
    Park I; Lee SH; Lee JL
    Clin Genitourin Cancer; 2018 Oct; 16(5):e997-e1002. PubMed ID: 29903415
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Left ventricular dysfunction associated with axitinib and nivolumab experience in an advanced renal cell carcinoma.
    Tanriverdi O; Ates S; Sandal KK; Uylas S; Bosna IC; Alkan A
    J Oncol Pharm Pract; 2020 Oct; 26(7):1765-1768. PubMed ID: 32164490
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparison of second-line treatments in metastatic renal cell carcinoma patients: A single-center experience.
    Pehlivan M; Paksoy N; Aydin E; Basaran M; Ekenel M
    Medicine (Baltimore); 2023 Oct; 102(41):e35245. PubMed ID: 37832108
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Treatment Outcome of Axitinib for Metastatic Renal-Cell Carcinoma Patients].
    Kusakabe N; Osawa T; Miyata H; Kikuchi H; Matsumoto R; Maruyama S; Abe T; Shinohara N
    Hinyokika Kiyo; 2018 Sep; 64(9):353-358. PubMed ID: 30369225
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Real world treatment sequences and outcomes for metastatic renal cell carcinoma.
    Lai GS; Li JR; Wang SS; Chen CS; Yang CK; Lin CY; Hung SC; Chiu KY; Yang SF
    PLoS One; 2023; 18(11):e0294039. PubMed ID: 37992086
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Podcast to Discuss Therapy Management for Patients with Metastatic Renal Cell Carcinoma Receiving First-Line Axitinib Plus an Immune Checkpoint Inhibitor.
    Ornstein MC; Wood LS
    Adv Ther; 2023 Sep; 40(9):3599-3609. PubMed ID: 37233877
    [No Abstract]   [Full Text] [Related]  

  • 18. Patterns, predictors and subsequent outcomes of disease progression in metastatic renal cell carcinoma patients treated with nivolumab.
    Zahoor H; Barata PC; Jia X; Martin A; Allman KD; Wood LS; Gilligan TD; Grivas P; Ornstein MC; Garcia JA; Rini BI
    J Immunother Cancer; 2018 Oct; 6(1):107. PubMed ID: 30333065
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Not Available].
    Borchiellini D
    Bull Cancer; 2018 Dec; 105 Suppl 3():S242-S254. PubMed ID: 30595153
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Initial Clinical Experience of Nivolumab for Metastatic Renal Cell Carcinoma].
    Fukunaga A; Yamasaki T; Okuno T; Imai K; Ikeuchi R; Hishiki K; Goto T; Sawada A; Negoro H; Akamatsu S; Saito R; Kobayashi T; Inoue T; Ogawa O
    Hinyokika Kiyo; 2018 Oct; 64(10):383-389. PubMed ID: 30543735
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.